Leads for Treating Methamphetamine Addiction
My name is Yamini Naidu and I am a sophomore at Valley Catholic High School in Beaverton, Oregon. I have been working on a science project about Methamphetamine (METH) addiction for the past two years, beginning in the summer of 2009. To those who read this blog, I wanted to share my research experience on METH so you could learn about the great potential for biochemistry that exists in the world of drugs and addiction. I received guidance for this project from the Oregon Health and Science University, the Portland American Chemical Society, and my high school chemistry and biology teachers. My research focuses on developing a treatment for METH addiction through computer modeling.
I was inspired to do this science project because I have had an interest in the brain and in neurology ever since my uncle passed away from stroke as a complication of heart disease. I was intrigued by the fact that METH can cause strokes in young abusers by a process still unknown to science. I hope that my research will not only help in the treatment of METH addiction but also in the treatment of stroke. At present, there is no effective treatment for controlling METH craving during withdrawal and abstinence. The goal of my research is to find or create a small molecule that can potentially block METH from binding to a special activation site (called Site I). Site I is located on a receptor protein in the brain called hTAAR1 (human Trace Amine-Associated Receptor 1). METH normally binds to this receptor like a key fits a lock – only a key with that shape can fit in the TAAR1 lock.
While experimenting with computer models, I discovered two new activation sites (which I call Sites II and III) on the receptor protein. I predicted that certain chemicals that prefer to bind to these new sites can change the shape of the receptor, making it impossible for METH to stick. If the lock changes, the old key can’t fit! So, guided by the computer-generated 3D structures of the two new TAAR1 binding sites, I designed new compounds and verified by computer that they would match the shape of the new activation sites. These new compounds may be preferred over others because their chemical structures and shape give them a stronger potential to bind to the receptor. The Oregon Health and Science University has filed a patent application on my discovery of the two binding sites and my invention of the novel compounds. My future goals are to synthesize and evaluate the compounds that I designed as potential new medication leads in laboratory trials and eventually in human trials.
I first presented my project at the regional Central Western Oregon Science Expo. Several expos and science fairs later, I was selected by Intel NWSE to represent the state of Oregon at ISEF as a finalist, where I competed with 1,500 high school student finalists from around the country and world. At ISEF, I was awarded the First Place Award of $3,000 in the biochemistry category. In addition, I was invited by the National Institute on Drug Abuse to give a talk on my research project in Washington, DC, this August. I have received recognition and rewards from many different organizations for my research, and I am happy now to share my great experience with more people.